Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

H. Lundbeck A/S Denmark

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II trial has recently been initiated to investigate the efficacy and safety of LuAG13909 for the potential treatment of CAH3

[phone]

[phone]

Palle Holm Olesen

Vice President, Investor Relations

[e-mail]

[phone]

About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has approximately 5,700 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

References:           

Merke DP, Auchus RJ. N Engl J Med 2020;383(13):1248-61           Claahsen-van der Grinten HL, et al. Endocr Rev 2022;43(1):91-159           Lundbeck. Data on file           Feldhaus AL, et al. Endocrinology 2017;158(1):1-8           Xing Y, et al. J Endocrinol 2011;209(3):327-35          Lousada LM, et al. Arch Endocrinol Metab 2021;65(4):488-94           Han TS, et al. Nat Rev Endocrinol 2014;10(2):115-24           Pofi R, et al. Clin Endocrinol (Oxf) 2023           Auchus RJ, et al. Front Endocrinol (Lausanne) 2022;13:1005963             

CONTACT:

H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
[phone]
[e-mail]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/h--lundbeck-a-s/r/lundbeck-receives-orphan-drug-designation-in-the-us-and-eu-for-lu-ag13909-for-the-treatment-of-patie,c4167538

The following files are available for download:

https://mb.cision.com/Main/18215/4167538/3518259.pdf

ACTH ODD Press release_Final

View original content:https://www.prnewswire.co.uk/news-releases/lundbeck-receives-orphan-drug-designation-in-the-us-and-eu-for-lu-ag13909-for-the-treatment-of-patients-with-congenital-adrenal-hyperplasia-302489326.html

@ prnewswire.co.uk